These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30560284)

  • 1. [Cochrane Rapid Review: the immune checkpoint inhibitor pembrolizumab versus chemotherapy for the treatment of advanced urothelial carcinoma].
    Wilborn D; Schmidt S
    Urologe A; 2019 Jan; 58(1):45-48. PubMed ID: 30560284
    [No Abstract]   [Full Text] [Related]  

  • 2. First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma.
    Tsimafeyeu I; Tjulandin S
    BJU Int; 2019 Apr; 123(4):563-565. PubMed ID: 30457694
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent advances in medical therapy for metastatic urothelial cancer.
    Yuasa T; Urakami S; Yonese J
    Int J Clin Oncol; 2018 Aug; 23(4):599-607. PubMed ID: 29556919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma.
    Powles T; Morrison L
    Nat Rev Urol; 2018 Oct; 15(10):585-587. PubMed ID: 30030491
    [No Abstract]   [Full Text] [Related]  

  • 5. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases.
    Sugihara Y; Kawai T; Yamada D; Furuyama C; Sato Y; Kume H
    Eur J Cancer; 2020 Feb; 126():91-92. PubMed ID: 31923731
    [No Abstract]   [Full Text] [Related]  

  • 7. [First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)].
    Rexer H; Ohlmann CH; Retz M
    Urologe A; 2017 May; 56(5):659-661. PubMed ID: 28349185
    [No Abstract]   [Full Text] [Related]  

  • 8. Pembrolizumab plus enfortumab vedotin in urothelial cancer.
    Santoni M; Takeshita H; Massari F; Bamias A; Cerbone L; Fiala O; Mollica V; Buti S; Santoni A; Bellmunt J
    Nat Rev Urol; 2024 Jul; 21(7):387-388. PubMed ID: 38267716
    [No Abstract]   [Full Text] [Related]  

  • 9. Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.
    Niegisch G
    N Engl J Med; 2024 Mar; 390(10):944-946. PubMed ID: 38446680
    [No Abstract]   [Full Text] [Related]  

  • 10. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
    Taguchi S; Kawai T; Nakagawa T; Kume H
    BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
    [No Abstract]   [Full Text] [Related]  

  • 11. Pembrolizumab in the treatment of advanced urothelial cancer.
    Lundgren KT; Farina MS; Bellmunt J
    Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report.
    Hunter L; Moser J; Sturge C; Barraza G; Colonna S
    J Oncol Pharm Pract; 2020 Jan; 26(1):216-219. PubMed ID: 30832555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Goto Y
    Int J Urol; 2023 Sep; 30(9):704. PubMed ID: 36482811
    [No Abstract]   [Full Text] [Related]  

  • 14. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprogression after pembrolizumab treatment in two patients with metastatic urothelial carcinoma.
    Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
    Jpn J Clin Oncol; 2019 May; 49(5):473-476. PubMed ID: 30920617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
    Bellmunt J; de Wit R; Vaughn DJ; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Poehlein CH; Perini RF; Bajorin DF;
    N Engl J Med; 2017 Mar; 376(11):1015-1026. PubMed ID: 28212060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramucirumab plus docetaxel for urothelial carcinoma.
    Baker H
    Lancet Oncol; 2016 Apr; 17(4):e140. PubMed ID: 26973322
    [No Abstract]   [Full Text] [Related]  

  • 18. Pembrolizumab for Advanced Urothelial Carcinoma.
    Venniyoor A
    N Engl J Med; 2017 Jun; 376(23):2302-3. PubMed ID: 28594151
    [No Abstract]   [Full Text] [Related]  

  • 19. Three Drugs Approved for Urothelial Carcinoma by FDA.
    Cancer Discov; 2017 Jul; 7(7):659-660. PubMed ID: 28546286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.